维生素C可以灭活狂犬病毒 （体外实验）
In vitro inactivation of the rabies virus by ascorbic acid
抗坏血酸体外灭活狂犬病病毒
抽象
目的：
目前推荐的狂犬病病毒灭活剂β丙内酯（BPL）非常昂贵并且可能具有致癌性。需要评估替代化学品，这将使病毒失活而不影响其抗原性。在该研究中，已经研究了抗坏血酸对狂犬病病毒感染性的影响。
方法：
将Vero细胞培养的固定狂犬病病毒CVS菌株用0.1mg / ml，0.5mg / ml和1mg / ml终浓度的抗坏血酸和5μg/ ml硫酸铜处理，并与未处理的病毒材料一起保持在4℃。使用小鼠接种和vero细胞滴定，在各种间隔后滴定每个等分试样用于病毒感染。通过小鼠中的抗体诱导和与用1：4000浓度的BPL灭活的病毒材料平行的改良NIH测试来确定病毒材料的抗原性。
结果：
最佳浓度为0.5mg / ml的抗坏血酸和5μg/ ml的硫酸铜在72小时后完全灭活病毒。灭活病毒保留了良好的抗原性和效力值，这与使用BPL相当。
结论：
这些发现表明，抗坏血酸可用作细胞培养中生长的固定狂犬病病毒的灭活剂，特别是用于制备诊断试剂。需要进一步的研究来评估其对细胞相关病毒的影响，可能的治疗潜力以及在灭活狂犬病疫苗生产中替代BPL的可行性。
In vitro inactivation of the rabies virus by ascorbic acid
Abstract
OBJECTIVE:
The current recommended inactivating agent for the rabies virus, beta propiolactone (BPL) is very expensive and potentially carcinogenic. There is a need to evaluate alternative chemicals, which will inactivate the virus without affecting its antigenicity. In this study the effect of ascorbic acid on the infectivity of the rabies virus has been investigated.
METHOD:
Vero cell grown fixed rabies virus CVS strain was treated with 0.1 mg/ml, 0.5 mg/ml and 1mg/ml final concentrations of ascorbic acid and 5 microg/ml of copper sulfate and kept at 4 degrees C along with untreated virus material. Each aliquot was titrated after various intervals for viral infectivity using both mice inoculation and titration in vero cells. The antigenicity of the virus material was determined by antibody induction in mice and modified NIH tests in parallel with virus material inactivated with a 1:4000 concentration of BPL.
RESULTS:
An optimal concentration of 0.5 mg/ml of ascorbic acid and 5 microg/ml of copper sulfate completely inactivated the virus after 72 hours. The inactivated virus retained good antigenicity and potency value, which was comparable with using BPL.
CONCLUSION:
These findings suggest that ascorbic acid can be used as an inactivating agent for fixed rabies virus grown in cell culture particularly for the preparation of diagnostic reagents. Further studies are required to evaluate its effect on the cell associated virus, probable therapeutic potential and feasibility of replacing BPL in production of inactivated rabies vaccine.
Int J Infect Dis. 2004 Jan;8(1):21-5.
Madhusudana SN1, Shamsundar R, Seetharaman S.
Author information
Department of Neurovirology, National Institute of Mental Health and Neurosciences (NIMHANS), Post Box 2900, Hosur Road, Bangalore 560029, India. mshampur@hotmail.com
PMID: 14690777
In vitro inactivation of the rabies virus by ascorbic acid. - PubMed - NCBI https://www.ncbi.nlm.nih.gov/pubmed/14690777
